Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Astrazeneca Plc (AZN.LN)

Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 216,434,292
  • Shares Outstanding, K 1,550,833
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales 5.00
  • Price/Cash Flow 20.14
  • Price/Book N/A
  • Price/Earnings ttm 28.73
  • Earnings Per Share ttm 6.54
  • Most Recent Earnings $1.49 on 02/10/26
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) 3.19 (1.69%)
  • Most Recent Dividend 1.595 on 02/19/26
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
12,356.000 +13.71%
on 04/23/26
15,449.998 -9.06%
on 04/10/26
-252.004 (-1.76%)
since 03/27/26
3-Month
12,356.000 +13.71%
on 04/23/26
15,732.000 -10.69%
on 02/18/26
+169.998 (+1.22%)
since 01/27/26
52-Week
9,651.000 +45.58%
on 05/12/25
15,732.000 -10.69%
on 02/18/26
+3,577.614 (+34.16%)
since 04/25/25

Most Recent Stories

More News
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD Business Wire - Mon Apr 20, 6:00AM CDT

Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer Business Wire - Thu Apr 2, 6:00AM CDT

IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver...

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD Business Wire - Fri Mar 27, 6:00AM CDT

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer Business Wire - Tue Mar 10, 7:30AM CDT

Joshua Jackson is joined by Gritty to take the body check off the ice.

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer Business Wire - Mon Mar 9, 6:00AM CDT

Based on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 ...

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting Business Wire - Fri Feb 20, 6:00AM CST

CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three...

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine Business Wire - Fri Feb 13, 6:00AM CST

Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol...

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US Business Wire - Wed Feb 11, 8:00AM CST

US ACT on Health Equity contributions support AstraZeneca’s long-term ambition in health equity and total more than $18 million to date

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
AstraZeneca results: FY and Q4 2025 Business Wire - Tue Feb 10, 6:00AM CST

Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Business Wire - Tue Feb 3, 6:00AM CST

Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo’s DATROWAY significantly improved overall survival vs. chemotherapy in this patient population ...

AZN : 189.75 (-1.33%)
AZN.LN : 14,036.000 (+0.57%)
More news for this symbol

Barchart Technical Opinion

buy

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 14,556.670
2nd Resistance Point 14,433.336
1st Resistance Point 14,194.668
Last Price 14,036.000
1st Support Level 13,832.666
2nd Support Level 13,709.332
3rd Support Level 13,470.664

See More

52-Week High 15,732.000
Last Price 14,036.000
Fibonacci 61.8% 13,409.058
Fibonacci 50% 12,691.500
Fibonacci 38.2% 11,973.941
52-Week Low 9,651.000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.